Chikungunya - 2 Studies Found
| RECRUITING |
: Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination : Chikungunya Virus Infection : 2024-11-21 : PXVX0317 vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP) 40mg, aluminum hydroxide 2% adjuvant, and formulation buffer suppl |
| COMPLETED |
: Phase 1 Study of SAR440894 vs Placebo : Chikungunya Virus Infection : 2024-11-21 : One time 60-minute IV infusion of lyophilized placebo for SAR440894 |